Valued at a market cap of $57.4 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions provider. The company specializes in pharmaceutical sourcing and distribution, providing a comprehensive range of services to healthcare providers and biopharmaceutical manufacturers throughout the U.S. and internationally.

Cencora is slated to announce its fiscal Q3 2025 earnings results on Wednesday, Aug. 06. Ahead of the event, analysts forecast the company to report an adjusted EPS of $3.78, up 13.2% from $3.34 in the year-ago quarter. COR has surpassed Wall Street's bottom-line estimates in the past four quarterly reports. 

For fiscal 2025, analysts project the prescription drug distributor to report adjusted EPS of $15.81, up 14.9% from $13.76 in fiscal 2024. 

Shares of Cencora have surged 35.9% over the past 52 weeks, outperforming both the S&P 500 Index's ($SPX) 11.9% rise and the Health Care Select Sector SPDR Fund's (XLV) nearly 7% decline over the same period.

Shares of Cencora rose 4.7% on May 7 after the company raised its annual adjusted EPS forecast to a range of $15.70 to $15.95, surpassing analysts’ average expectations. The upward revision was driven by strong demand for high-cost specialty medicines and GLP-1 weight-loss drugs, which significantly boosted revenue. Additionally, the company posted Q2 2025 adjusted profit of $4.42 per share and revenue of $75.5 billion, both exceeding analyst estimates.

Analysts' consensus rating on Cencora stock is bullish, with an overall “Strong Buy” rating. Among 15 analysts covering the stock, 12 recommend a "Strong Buy” and three give a "Hold" rating. This configuration is slightly more bullish than three months ago, with 11 analysts suggesting a "Strong Buy."

As of writing, the stock is trading below the average analyst price target of $329.